| 发明名称 | Selective elimination of erosive cells | ||
| 摘要 | The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody. | ||
| 申请公布号 | US9512228(B2) | 申请公布日期 | 2016.12.06 |
| 申请号 | US201214124876 | 申请日期 | 2012.06.18 |
| 申请人 | NOVO NORDISK A/S | 发明人 | Soederstroem Kalle;Galsgaard Elisabeth Douglas |
| 分类号 | A61K39/395;C07K16/28 | 主分类号 | A61K39/395 |
| 代理机构 | Saliwanchik, Lloyd & Eisenschenk | 代理人 | Saliwanchik, Lloyd & Eisenschenk |
| 主权项 | 1. A method for treating cartilage destruction or bone erosion in a subject having osteoarthritis: comprising administering an anti-NKG2A antibody, or an antigen binding fragment thereof, to said subject, wherein said antibody blocks inhibitory signaling by CD94-NKG2A receptors and is a non-depleting antibody. | ||
| 地址 | Bagsvaerd DK | ||